https://orcid.org/0000-0001-5904-6028
References
- Robinson J, Lee VH. Controlled drug delivery: fundamentals and applications. Boca Raton (FL): CRC Press; 1987.
- Das NG, Das SK. Controlled release of oral dosage forms. Pharm Technol. 2003;15:10–17.
- Salsa T, Veiga F, Pina ME. Oral controlled-release dosage forms. I. Cellulose ether polymers in hydrophilic matrices. Drug Dev Ind Pharm. 1997;23:929–938.
- Shelke S, Shahi S, Jadhav K, et al. Thermoreversible nanoethosomal gel for the intranasal delivery of Eletriptan hydrobromide. J Mater Sci Mater Med. 2016;27:103.
- Washington N, Washington C, Wilson C. Physiological pharmaceutics: barriers to drug absorption. Boca Raton (FL): CRC Press. 2000.
- Goodin S, Cunningham R. 5-HT3-receptor antagonists for the treatment of nausea and vomiting: a reappraisal of their side-effect profile. Oncologist. 2002;7:424–436.
- Pearman MH. Single dose intravenous ondansetron in the prevention of postoperative nausea and vomiting. Anaesthesia. 1994;49:11–15.
- Chaffee BJ, Tankanow RM. Ondansetron-the first of a new class of antiemetic agents. Clin Pharm. 1991;10:430–446.
- Mishra B, Makesh BK, Sankar C. Oral push-pull osmotic pumps of pentazocine hydrochloride: Development and evaluation. Indian J Pharm Sci. 2006;68:85.
- Verma RK, Mishra B, Garg S. Osmotically controlled oral drug delivery. Drug Dev Ind Pharm. 2000;26:695–708.
- Kiil F. Molecular mechanisms of osmosis. Am J Physiol. 1989;256:R801–8.
- Zhang ZH, Dong HY, Peng B, et al. Design of an expert system for the development and formulation of push–pull osmotic pump tablets containing poorly water-soluble drugs. Int J Pharm. 2011;410:41–47.
- Missaghi S, Patel P, Farrell TP, et al. Investigation of critical core formulation and process parameters for osmotic pump oral drug delivery. AAPS PharmSciTech. 2014;15:149–160.
- Jain JM, Sakarkar DM, Abdul S, et al. Multilayer tablet technology–options and opportunities. Res J Pharm Technol. 2010;3:368–378.
- Liu L, Xu X. Preparation of bilayer-core osmotic pump tablet by coating the indented core tablet. Int J Pharm. 2008;352:225–230.
- Agrawal G, Wakte P, Shelke S. Formulation optimization of human insulin loaded microspheres for controlled oral delivery using response surface methodology. Endocr Metab Immune Disord Drug Targets. 2017;17:149–165.
- Agrawal GR, Wakte P, Shelke S. Formulation, physicochemical characterization and in vitro evaluation of human insulin-loaded microspheres as potential oral carrier. Prog Biomater. 2017;6:125–136.
- Shelke S, Shahi S, Jalalpure S, et al. Poloxamer 407-based intranasal thermoreversible gel of zolmitriptan-loaded nanoethosomes: Formulation, optimization, evaluation and permeation studies. J Liposome Res. 2016;26:313–323.
- Food and Drug Administration. Guidance for industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. Rockville (MD): Center for Drug Evaluation and Research; 2005.
- Jinno JI, Kamada Miyake NM, Yamada K, et al. Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. J Control Release. 2006;10:56–64.
- Sawant S, Barge V. A validated stability indicating RP-HPLC method for valganciclovir, identification and characterization of forced degradation products of valganciclovir using LC-MS/MS. ActaChromatographica. 2014;1:29–42.
- Singh o, Saxena S, Mishra S, et al. Determination of valganciclovir and ganciclovir in human plasma by liquid chromatography tandem mass spectrometric detection. Clin Biochem. 2011;44:907–915.